Sign Up to like & get
recommendations!
1
Published in 2021 at "European journal of medicinal chemistry"
DOI: 10.1016/j.ejmech.2021.113195
Abstract: Cystic fibrosis (CF) is the most frequent life-limiting autosomal recessive disorder in the Caucasian population. It is due to mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene. Current symptomatic CF therapies, which treat…
read more here.
Keywords:
cftr updates;
development future;
clinical development;
future directions ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2025 at "Chemical Society reviews"
DOI: 10.1039/d5cs00366k
Abstract: Hydroxylamine (NH2OH) is a crucial raw material and chemical intermediate with significant applications in medicine, materials science, and semiconductor industries. Conventional synthetic methods for NH2OH are usually accompanied by high energy consumption and environmental pollution.…
read more here.
Keywords:
development future;
recent development;
hydroxylamine;
electrosynthesis nh2oh ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2024 at "Frontiers in Bioengineering and Biotechnology"
DOI: 10.3389/fbioe.2024.1373130
Abstract: Ureteral stenting is a common clinical procedure for the treatment of upper urinary tract disorders, including conditions such as urinary tract infections, tumors, stones, and inflammation. Maintaining normal renal function by preventing and treating ureteral…
read more here.
Keywords:
ureteral stents;
development future;
recent development;
urinary tract ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2023 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2023.1043109
Abstract: In the present scenario, immunization is of utmost importance as it keeps us safe and protects us from infectious agents. Despite the great success in the field of vaccinology, there is a need to not…
read more here.
Keywords:
age vaccine;
vaccine adjuvants;
new age;
development future ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Biomolecules"
DOI: 10.3390/biom13010088
Abstract: Efavirenz (Sustiva®) is a first-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) used to treat human immunodeficiency virus (HIV) type 1 infection or to prevent the spread of HIV. In 1998, the FDA authorized efavirenz for the…
read more here.
Keywords:
efavirenz;
hiv;
efavirenz history;
development future ... See more keywords